Literature DB >> 17941498

Neuroradiological findings of bleomycin leakage in cystic craniopharyngioma. Report of three cases.

Lucie Lafay-Cousin1, Ute Bartels, Charles Raybaud, Abhaya V Kulkarni, Sharon Guger, Annie Huang, Eric Bouffet.   

Abstract

Intracystic bleomycin therapy has been proposed as a treatment for predominantly cystic craniopharyngioma. The risks of using this therapy, however, have not been clearly identified. The authors report on three children treated with intracystic bleomycin who developed initially mild symptoms during their course of therapy. They describe the neuroimaging findings from computed tomography (CT) scans and magnetic resonance (MR) images and the medical management of these three cases. Two patients in whom craniopharyngioma was recently diagnosed and one patient with recurrent craniopharyngioma were treated with a course of 3 mg of intracystic bleomycin three times a week for 5 weeks, followed by once every week for 10 weeks. All patients had a negative reservoir permeability test prior to beginning intracystic bleomycin therapy. Patients were asymptomatic or had mild symptoms at the time of neuroimaging. Magnetic resonance images revealed extensive vasogenic edema surrounding the cyst in all three patients, consistent with signs of bleomycin leakage. The edema occurred near the time of the 12th injection in two patients, and at the end of treatment in the remaining patient. Subsequently, two patients developed further symptoms suggestive of hypothalamic injury. These two patients received corticosteroids, leading to a rapid and sustained clinical improvement. Follow-up serial MR images showed a progressive regression of the surrounding edema. Neuroimaging documentation of bleomycin toxicity has been described mainly in adults experiencing severe toxicity. There was no correlation between clinical symptoms and the extent of edema in these three patients. An MR image provides a higher resolution than CT scans for evaluating the adjacent cerebral structures and is very sensitive in detecting early abnormalities, even in asymptomatic patients. Bleomycin therapy requires close clinical monitoring. Imaging evaluation should be performed using MR imaging during treatment to ensure the safety of the therapy. In the authors' experience, the toxicity to bleomycin was transient. Management of the toxicity using high-dose steroid administration appears to contribute to controlling the bleomycin-induced inflammatory process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17941498     DOI: 10.3171/PED-07/10/318

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  9 in total

Review 1.  Intracystic bleomycin for cystic craniopharyngiomas in children.

Authors:  Si Zhang; Yuan Fang; Bo Wen Cai; Jian Guo Xu; Chao You
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

2.  Optimal treatment strategy for craniopharyngiomas based on long-term functional outcomes of recent and past treatment modalities.

Authors:  Takakazu Kawamata; Kosaku Amano; Yasuo Aihara; Osami Kubo; Tomokatsu Hori
Journal:  Neurosurg Rev       Date:  2010-01       Impact factor: 3.042

3.  Treatment of Cystic Craniopharyngiomas: An Update.

Authors:  Federico Bianchi; Alberto Benato; Luca Massimi
Journal:  Adv Tech Stand Neurosurg       Date:  2022

4.  Trends in treatment and outcomes of pediatric craniopharyngioma, 1975-2011.

Authors:  Michal Cohen; Ute Bartels; Helen Branson; Abhaya V Kulkarni; Jill Hamilton
Journal:  Neuro Oncol       Date:  2013-03-13       Impact factor: 12.300

5.  Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.

Authors:  Stewart Goldman; Ian F Pollack; Regina I Jakacki; Catherine A Billups; Tina Y Poussaint; Adekunle M Adesina; Ashok Panigrahy; Donald W Parsons; Alberto Broniscer; Giles W Robinson; Nathan J Robison; Sonia Partap; Lindsay B Kilburn; Arzu Onar-Thomas; Ira J Dunkel; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

6.  Intracystic therapies for cystic craniopharyngioma in childhood.

Authors:  Ute Bartels; Normand Laperriere; Eric Bouffet; James Drake
Journal:  Front Endocrinol (Lausanne)       Date:  2012-03-27       Impact factor: 5.555

7.  Long term sequelae of pediatric craniopharyngioma - literature review and 20 years of experience.

Authors:  Michal Cohen; Sharon Guger; Jill Hamilton
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-28       Impact factor: 5.555

8.  Endoscopic Transcortical Transventricular Management of Cystic Craniopharyngioma: Outcome Analysis of 32 Cases at a Tertiary Care Center.

Authors:  Somil Jaiswal; Manish Jaiswal; Pooja Jaiswal; Ankur Bajaj; Chhitij Srivastava; Anil Chandra; Bal Krishna Ojha; Janu Vikas; Awadhesh Yadav
Journal:  Asian J Neurosurg       Date:  2020-12-21

Review 9.  Current Advances in the Management of Adult Craniopharyngiomas.

Authors:  Montserrat Lara-Velazquez; Yusuf Mehkri; Eric Panther; Jairo Hernandez; Dinesh Rao; Peter Fiester; Raafat Makary; Michael Rutenberg; Daryoush Tavanaiepour; Gazanfar Rahmathulla
Journal:  Curr Oncol       Date:  2022-03-04       Impact factor: 3.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.